2025-01-17 05:47:28
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne
Health/ 2023-07-22
Ascletis Announces First Patient Dosed i...

HANGZHOU and SHAOXING,China,Jan. 13,2022--Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II ...

Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
Health/ 2023-07-22
Dermaliq Therapeutics Signs USD 15 Milli...

WILMINGTON,Del.,Jan. 18,2022--Novaliq GmbH,3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establis...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release